Serum fibroblast growth factor-23 and incident hypertension: The Atherosclerosis Risk in Communities (ARIC) Study

Journal of Hypertension

Volumn 34, Issue 7, 2016, Pages 1266-1272

  Fyfe Johnson, Amber L ^a   Alonso, Alvaro ^a   Selvin, Elizabeth ^b,c   Bower, Julie K ^d   Pankow, James S ^a   Agarwal, Sunil K ^e   Lutsey, Pamela L ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d OHIO STATE UNIVERSITY   (United States)

^e MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Atherosclerosis Risk in Communities Study; fibroblast growth factor 23; fibroblast growth factors; hypertension; risk factors

Indexed keywords

CALCIUM; FIBROBLAST GROWTH FACTOR 23; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; PHOSPHORUS; TRIACYLGLYCEROL; FIBROBLAST GROWTH FACTOR;

ADULT; ARTICLE; BLOOD PRESSURE; CALCIUM BLOOD LEVEL; CARDIOVASCULAR RISK; COHORT ANALYSIS; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; INCIDENCE; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; OBESITY; PHOSPHATE BLOOD LEVEL; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; RISK FACTOR;

COHORT STUDIES; FEMALE; FIBROBLAST GROWTH FACTORS; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; INCIDENCE; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RISK FACTORS;

EID: 84964378437     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0000000000000936     Document Type: Article

References (49)

1. Li C, Balluz LS, Ford ES, Okoro CA, Zhao G, Pierannunzi C. A comparison of prevalence estimates for selected health indicators and chronic diseases or conditions from the Behavioral Risk Factor Surveillance System, the National Health Interview Survey, and the National Health and Nutrition Examination Survey, 2007-2008. Prev Med (Baltim) 2012; 54: 381-387.
2. Crescioni M, Gorina Y, Bilheimer L, Gillum RF. Trends in health status and healthcare use among older men. Natl Health Stat Rep 2010; 1-18.
3. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al. Heart disease and stroke statistics-2015 update: a report from the American Heart Association. Circulation 2015; 131: e29-322.
4. Lifton RP, Gharavi AG, Geller DS. Molecular mechanisms of human hypertension. Cell 2001; 104: 545-556.
5. Hu MC, Shiizaki K, Kuro-o M, Moe OW. Fibroblast growth factor 23 and Klotho: physiology and pathophysiology of an endocrine network of mineral metabolism. Annu Rev Physiol 2013; 75: 503-533.
6. Faul C. Fibroblast growth factor 23 and the heart. Curr Opin Nephrol Hypertens 2012; 21: 369-375.
7. Dalal M, Sun K, Cappola AR, Ferrucci L, Crasto C, Fried LP, et al. Relationship of serum fibroblast growth factor 23 with cardiovascular disease in older community-dwelling women. Eur J Endocrinol 2011; 165: 797-803.
8. Ärnlöv J, Carlsson AC, SundströmJ, Ingelsson E, Larsson A, Lind L, et al. Serum FGF23 and risk of cardiovascular events in relation to mineral metabolism and cardiovascular pathology. Clin J Am Soc Nephrol 2013; 8: 781-786.
9. Lutsey PL, Alonso A, Selvin E, Pankow JS, Michos ED, Agarwal SK, et al. Fibroblast growth factor-23 and incident coronary heart disease, heart failure, and cardiovascular mortality: the atherosclerosis risk in communities study. J Am Heart Assoc 2014; 3: e000936.
10. Isakova T, Xie H, Yang W, Xie D, Anderson AH, Scialla J, et al. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 2011; 305: 2432-2439.
11. Gutiérrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah H, et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008; 359: 584-592.
12. Kendrick J, Cheung AK, Kaufman JS, Greene T, Roberts WL, Smits G, et al. FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis. J Am Soc Nephrol 2011; 22: 1913-1922.
13. Andrukhova O, Slavic S, Smorodchenko A, Zeitz U, Shalhoub V, Lanske B, et al. FGF23 regulates renal sodium handling and blood pressure. EMBO Mol Med 2014; 6: 744-759.
14. Andrukhova O, Smorodchenko A, Egerbacher M, Streicher C, Zeitz U, Goetz R, et al. FGF23 promotes renal calcium reabsorption through the TRPV5 channel. EMBO J 2014; 33: 229-246.
15. Parker BD, Schurgers LJ, Brandenburg VM, Christenson RH, Vermeer C, Ketteler M, et al. The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the Heart and Soul Study. Ann Intern Med 2010; 152: 640-648.
16. Ix JH, Katz R, Kestenbaum BR, de Boer IH, Chonchol M, Mukamal KJ, et al. Fibroblast growth factor-23 and death, heart failure, and cardiovascular events in community-living individuals: CHS (Cardiovascular Health Study). J Am Coll Cardiol 2012; 60: 200-207.
17. The ARIC investigators. The Atherosclerosis Risk in Communities (ARIC) study: design and objectives. The ARIC investigators. Am J Epidemiol 1989; 129: 687-702.
18. Baecke JA, Burema J, Frijters JE. A short questionnaire for the measurement of habitual physical activity in epidemiological studies. Am J Clin Nutr 1982; 36: 936-942.
19. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
20. Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T, et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med 2012; 367: 20-29.
21. Atherosclerosis Risk in Communities (ARIC) study operations manual 11, Visit 4. 1997. https: www2.cscc.unc.eduariccohort-manuals
22. Bower JK, Appel LJ, Matsushita K, Young JH, Alonso A, Brancati FL, et al. Glycated hemoglobin and risk of hypertension in the atherosclerosis risk in communities study. Diabetes Care 2012; 35: 1031-1037.
23. Allison PD. Survival analysis using SAS: a practical guide, 12th ed. Cary, NC: SAS Publishing 2008.
24. Zajaç M, Rybi-Szumińska A, Wasilewska A. Urine fibroblast growth factor 23 levels in hypertensive children and adolescents. Croat Med J 2015; 56: 344-350.
25. Heine GH, Seiler S, Fliser D. FGF-23: the rise of a novel cardiovascular risk marker in CKD. Nephrol Dial Transplant 2012; 27: 3072-3081.
26. Foley RN, Collins AJ, Herzog CA, Ishani A, Kalra PA. Serum phosphorus levels associate with coronary atherosclerosis in young adults. J Am Soc Nephrol 2009; 20: 397-404.
27. Sabanayagam C, Shankar A. Serum calcium levels and hypertension among U.S. adults. J Clin Hypertens (Greenwich) 2011; 13: 716-721.
28. Intersalt Cooperative Research Group. Intersalt: an international study of electrolyte excretion and blood pressure. Results for 24 hour urinary sodium and potassium excretion. Intersalt Cooperative Research Group. BMJ 1988; 297: 319-328.
29. Elliott P, Stamler J, Nichols R, Dyer AR, Stamler R, Kesteloot H, et al. Intersalt revisited: further analyses of 24 h sodium excretion and blood pressure within and across populations. Intersalt Cooperative Research Group. BMJ 1996; 312: 1249-1253.
30. Graudal NA, Galløe AM, Garred P. Effects of sodium restriction on blood pressure, renin, aldosterone, catecholamines, cholesterols, and triglyceride: a meta-Analysis. JAMA 1998; 279: 1383-1391.
31. Midgley JP, Matthew AG, Greenwood CM, Logan AG. Effect of reduced dietary sodium on blood pressure: a meta-Analysis of randomized controlled trials. JAMA 1996; 275: 1590-1597.
32. Appel LJ, Moore TJ, Obarzanek E, Vollmer WM, Svetkey LP, Sacks FM, et al. A clinical trial of the effects of dietary patterns on blood pressure. DASHCollaborative Research Group.NEngl JMed 1997; 336: 1117-1124.
33. Whelton PK, He J, Cutler JA, Brancati FL, Appel LJ, Follmann D, et al. Effects of oral potassium on blood pressure. Meta-Analysis of randomized controlled clinical trials. JAMA 1997; 277: 1624-1632.
34. Sacks FM, Svetkey LP, Vollmer WM, Appel LJ, Bray GA, Harsha D, et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med 2001; 344: 3-10.
35. Bergwitz C, Jüppner H. Regulation of phosphate homeostasis by PTH, vitamin D, and FGF23. Annu Rev Med 2010; 61: 91-104.
36. Jüppner H, Wolf M, Salusky IB. FGF-23: more than a regulator of renal phosphate handling? J Bone Miner Res 2010; 25: 2091-2097.
37. Elliott P, Kesteloot H, Appel LJ, Dyer AR, Ueshima H, Chan Q, et al. Dietary phosphorus and blood pressure: international study of macroand micro-nutrients and blood pressure. Hypertension 2008; 51: 669-675.
38. Salem MM. Pathophysiology of hypertension in renal failure. Semin Nephrol 2002; 22: 17-26.
39. Zoccali C, Yilmaz MI, Mallamaci F. FGF23: a mature renal and cardiovascular risk factor? Blood Purif 2013; 36: 52-57.
40. Wolf M. Update on fibroblast growth factor 23 in chronic kidney disease. Kidney Int 2012; 82: 737-747.
41. Stevens KK, McQuarrie EP, Sands W, Hillyard DZ, Patel RK, Mark PB, et al. Fibroblast growth factor 23 predicts left ventricular mass and induces cell adhesion molecule formation. Int J Nephrol 2011; 2011: 297070.
42. Mirza MAI, Larsson A, Lind L, Larsson TE. Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the community. Atherosclerosis 2009; 205: 385-390.
43. Yilmaz MI, Sonmez A, Saglam M, Yaman H, Kilic S, Demirkaya E, et al. FGF-23 and vascular dysfunction in patients with stage 3 and 4 chronic kidney disease. Kidney Int 2010; 78: 679-685.
44. Manghat P, Fraser WD, Wierzbicki AS, Fogelman I, Goldsmith DJ, Hampson G. Fibroblast growth factor-23 is associated with C-reactive protein, serum phosphate and bone mineral density in chronic kidney disease. Osteoporos Int 2010; 21: 1853-1861.
45. Munoz Mendoza J, Isakova T, Ricardo AC, Xie H, Navaneethan SD, Anderson AH, et al. Fibroblast growth factor 23 and Inflammation in CKD. Clin J Am Soc Nephrol 2012; 7: 1155-1162.
46. Koiwa F, Kazama JJ, Tokumoto A, Onoda N, Kato H, Okada T, et al. Sevelamer hydrochloride and calcium bicarbonate reduce serum fibroblast growth factor 23 levels in dialysis patients. Ther Apher Dial 2005; 9: 336-339.
47. Nagano N, Miyata S, Abe M, Kobayashi N, Wakita S, Yamashita T, et al. Effect of manipulating serum phosphorus with phosphate binder on circulating PTH and FGF23 in renal failure rats. Kidney Int 2006; 69: 531-537.
48. Pande S, Ritter CS, Rothstein M, Wiesen K, Vassiliadis J, Kumar R, et al. FGF-23 and sFRP-4 in chronic kidney disease and postrenal transplantation. Nephron Physiol 2006; 104: 23-32.
49. Isakova T, Gutiérrez OM, Smith K, Epstein M, Keating LK, Juppner H, et al. Pilot study of dietary phosphorus restriction and phosphorus binders to target fibroblast growth factor 23 in patients with chronic kidney disease. Nephrol Dial Transplant 2011; 26: 584-591.